Avalo Therapeutics (AVTX) Accumulated Expenses (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Accumulated Expenses data on file, last reported at $11.2 million in Q1 2026.

• Quarterly Accumulated Expenses rose 145.8% year-over-year to $11.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.2 million (up 145.8% YoY) and the FY2025 annual result came in at $12.8 million, up 102.68% from the prior year.
• Accumulated Expenses slipped to $11.2 million in Q1 2026, from $12.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $14.1 million in Q1 2022 to a low of $4.2 million in Q4 2023.
• A 5-year average of $8.9 million and a median of $7.6 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses slumped 68.43% — and 2026, when it surged 145.8%.
• Tracing AVTX's Accumulated Expenses over 5 years: stood at $13.2 million in 2022, then tumbled by 68.43% to $4.2 million in 2023, then surged by 51.41% to $6.3 million in 2024, then surged by 102.68% to $12.8 million in 2025, then slipped by 12.18% to $11.2 million in 2026.
• The last three Accumulated Expenses figures came in at $11.2 million (Q1 2026), $12.8 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.